2018 Fiscal Year Final Research Report
Cervical cancer stem cell model derived from iPS cells to investigate new therapeutic targets
| Project/Area Number |
16K11131
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Research Institute for Clinical Oncology, Saitama Cancer Center |
|---|
Principal Investigator |
Adachi Katsuyuki 埼玉県立がんセンター(臨床腫瘍研究所), 病院 婦人科, 副部長 (90735200)
|
|---|
| Research Collaborator |
Kawana Kei
Sato Masakazu
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Keywords | 子宮頸癌 / iPSC / 組織幹細胞 / リザーブ細胞 / 個別化医療 |
|---|
| Outline of Final Research Achievements |
We established a reserve cell model that exists in SCJ from human iPS cells via intermediate mesoderm. The iPS cell-derived reserve cells expressed SCJ markers such as CK7, AGR2, CD63 and MMP7. When the culture conditions were changed, iPS cell-derived reserve cells were partially differentiated into squamous epithelium and partly into glandular epithelium. It is important findings that these cells are reserve cells. Then, cervical cancer stem cells into which HPV16 and HPV18 genes introduced were established. Based on the findings obtained in this study, establishing a cancer stem cell model for cervical cancer from the patient's own cell-derived iPS cells will lead to further personalized medicine.
|
| Free Research Field |
婦人科悪性腫瘍
|
| Academic Significance and Societal Importance of the Research Achievements |
子宮頸癌は婦人科悪性腫瘍の中で乳癌についで多い疾患である。近年では子宮頸癌検診の推進で早期でみつかる症例も増えているが、一方で再発症例については未だ治療の選択肢が少ない。一般的な化学療法だけではなく今後はより個別的な新規な治療開発が望まれているため、本研究は子宮頸癌の癌幹細胞に着目しその特徴から患者の個別化するための治療標的分子を見つけることに注力した。iPSCより子宮頸癌の癌幹細胞モデル樹立を目指し一部達成した。これは将来的には癌患者個人よりiPSCを樹立し、個別の子宮頸癌癌幹細胞モデルを使用し薬剤感受性テストやその他の治療感受性テストを行うことで個別化医療への応用が可能となると期待する。
|
